IN2014CH00390A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CH00390A IN2014CH00390A IN390CH2014A IN2014CH00390A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A IN 390CH2014 A IN390CH2014 A IN 390CH2014A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A
- Authority
- IN
- India
- Prior art keywords
- neu
- peptide
- her2
- cellular immunity
- provides
- Prior art date
Links
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 abstract 2
- 101150029707 ERBB2 gene Proteins 0.000 abstract 2
- 230000007969 cellular immunity Effects 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013020799 | 2013-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CH00390A true IN2014CH00390A (pl) | 2015-07-31 |
Family
ID=50028736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN390CH2014 IN2014CH00390A (pl) | 2013-02-05 | 2014-01-29 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140220100A1 (pl) |
| EP (1) | EP2762158A1 (pl) |
| JP (1) | JP2014169278A (pl) |
| KR (1) | KR20140100415A (pl) |
| CN (1) | CN103961696A (pl) |
| CA (1) | CA2840997A1 (pl) |
| IN (1) | IN2014CH00390A (pl) |
| RU (1) | RU2014102938A (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2687144C2 (ru) | 2013-02-05 | 2019-05-07 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения |
| CA2841014A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Tape preparation of wt1 peptide cancer vaccine for transdermal administration |
| BR112017006599A2 (pt) * | 2014-10-02 | 2017-12-19 | Nitto Denko Corp | composição farmacêutica de vacina para administração transdérmica |
| WO2021078761A1 (en) * | 2019-10-24 | 2021-04-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of fingolimod |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| EP2316482A1 (en) * | 2001-03-19 | 2011-05-04 | Intercell USA, Inc. | Transcutaneous immunostimulation |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| JP4887284B2 (ja) | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
| DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| CA2523032A1 (en) * | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| US20090317414A1 (en) * | 2006-07-25 | 2009-12-24 | 4G Vaccines Pty Ltd | Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |
| US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
| SI2162149T1 (sl) * | 2007-06-01 | 2014-04-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Cepivo za preprečevanje relapsa raka na dojki |
| JP5661735B2 (ja) * | 2009-04-01 | 2015-01-28 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
| CN102475886A (zh) * | 2010-11-29 | 2012-05-30 | 南开大学 | 新型抗乳腺癌多肽疫苗 |
-
2014
- 2014-01-29 IN IN390CH2014 patent/IN2014CH00390A/en unknown
- 2014-01-29 CN CN201410043336.6A patent/CN103961696A/zh active Pending
- 2014-01-29 US US14/166,952 patent/US20140220100A1/en not_active Abandoned
- 2014-01-29 KR KR1020140011625A patent/KR20140100415A/ko not_active Application Discontinuation
- 2014-01-29 CA CA2840997A patent/CA2840997A1/en not_active Abandoned
- 2014-01-29 JP JP2014014804A patent/JP2014169278A/ja active Pending
- 2014-01-29 RU RU2014102938/10A patent/RU2014102938A/ru not_active Application Discontinuation
- 2014-01-29 EP EP14000323.7A patent/EP2762158A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2840997A1 (en) | 2014-08-05 |
| JP2014169278A (ja) | 2014-09-18 |
| EP2762158A1 (en) | 2014-08-06 |
| RU2014102938A (ru) | 2015-08-10 |
| US20140220100A1 (en) | 2014-08-07 |
| KR20140100415A (ko) | 2014-08-14 |
| CN103961696A (zh) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| IN2014CH00396A (pl) | ||
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| IN2014CH00391A (pl) | ||
| PH12016501411A1 (en) | Bifunctional cytotoxic agents | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
| MX2016004570A (es) | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. | |
| MX2015013203A (es) | Conjugados de anticuerpo - farmaco. | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
| MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
| IN2014CH00393A (pl) | ||
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| IN2014CH00395A (pl) | ||
| MY191539A (en) | Streptococcal vaccine | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX2016005285A (es) | Conjugados de somatostatina y sus analagos. | |
| IN2014CH00386A (pl) | ||
| IN2014CH00390A (pl) |